You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodies needed for the development of new biologics.
The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.
The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.
Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.
HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.
The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
Time magazine looks into how liquid biopsies are changing cancer care.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.